UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction | (Commission | (IRS Employer | ||
of Incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Appointment of a Director.
On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies. The Board has also appointed Ms. Carter as the Chair of its Audit Committee. She replaces Shimon Rapps who will remain as a member of the Audit Committee.
Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held various senior roles with Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for their $9B Neuroscience division. In addition, during her tenure at Medtronic she grew the Gastrointestinal Solutions division from early tech start-up acquisition of $36M to revenue of $450M in 5 years through organic growth and multiple acquisitions. Prior to Medtronic, Ms. Carter served as Director of Finance at Boston Scientific and as VP of Accounting and Reporting at UnitedHealth Group. Prior to that, she served as Assistant Controller for Arterial Vascular Engineering, where she was instrumental in guiding the rapid growth of the company from 200 employees to over 4,000 in under five years. During this time, she managed the integration of two acquisitions and subsequently that company’s sale to Medtronic.
Ms. Carter holds a B.S. in Business Administration from California Polytech State University and is a Certified Public Accountant (inactive) in the State of California.
The Board believes that Ms. Carter is suited to be a Director of the Company due to her various senior finance roles, including serving as CFO of Medtronic, as well as her longstanding experience as an executive for life science companies.
Item 9.01 Exhibits
Exhibit | Inline XBRL | |
104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 31, 2023
GLUCOTRACK, INC. | ||
By: | /s/ Jolie Kahn | |
Name: | Jolie Kahn | |
Title: | Chief Financial Officer |
Cover |
Aug. 25, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 25, 2023 |
Entity File Number | 001-41141 |
Entity Registrant Name | GLUCOTRACK, INC. |
Entity Central Index Key | 0001506983 |
Entity Tax Identification Number | 98-0668934 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 301 Rte 17 North |
Entity Address, Address Line Two | Ste. 800 |
Entity Address, City or Town | Rutherford |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07070 |
City Area Code | (201) |
Local Phone Number | 842-7715 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | GCTK |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
>3J]!S(L>^#%Z87[QOD$ JQ"(6
M,P$ "(" / " 5<0 !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4 " !4BA]7)!Z;HJT #X 0 &@ @ &W$0 >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !4BA]799!YDAD!
M #/ P $P @ &<$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08 "0 ) #X" #F$P !
end
RHY_U=3_ 102P,$% @
M5(H?5Y>*NQS $P( L !?
LX6,<&'U4]-P$+T8^1 .&U0$KV/@[)\2H71
MPK$]Q9'0MP6+T/+2/04?V94@^#9'9QB_#DBTBWS*3"4